TNFRSF17 and cancer: Recent advances in adoptive immunotherapy of cancer have led to the Food and Drug Administration (FDA) approval of CAR T-cells targeting CD19 and B-cell maturation antigen (BCMA) for advanced B-cell malignancies or relapsed/refractory B-cell malignancies.